These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37939991)

  • 41. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
    Cunningham JW; Vaduganathan M; Claggett BL; Zile MR; Anand IS; Packer M; Zannad F; Lam CSP; Janssens S; Jhund PS; Kober L; Rouleau J; Shah SJ; Chopra VK; Shi VC; Lefkowitz MP; Prescott MF; Pfeffer MA; McMurray JJV; Solomon SD
    JACC Heart Fail; 2020 May; 8(5):372-381. PubMed ID: 32241619
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
    Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
    JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction.
    Jia R; Ji Y; Sun D
    Biomed Pharmacother; 2022 Nov; 155():113701. PubMed ID: 36116249
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Angiotensin II receptor Neprilysin inhibitor (LCZ696) compared to Valsartan attenuates Hepatotoxicity in STZ-induced hyperglycemic rats.
    Alqahtani F; Mohany M; Alasmari AF; Alanazi AZ; Belali OM; Ahmed MM; Al-Rejaie SS
    Int J Med Sci; 2020; 17(18):3098-3106. PubMed ID: 33173431
    [No Abstract]   [Full Text] [Related]  

  • 45. The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review.
    Zhang R; Sun X; Li Y; He W; Zhu H; Liu B; Zhang A
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484211058681. PubMed ID: 34994233
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Qiliqiangxin capsule improves cardiac remodeling in rats with DOCA-salt-induced diastolic dysfunction.
    Hao JM; Sun P; Zeng Y; Zhang H; Zhang ZD; Chang LP; Hou YL
    Eur Rev Med Pharmacol Sci; 2023 Aug; 27(15):7264-7275. PubMed ID: 37606135
    [TBL] [Abstract][Full Text] [Related]  

  • 47. LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease.
    Suematsu Y; Jing W; Nunes A; Kashyap ML; Khazaeli M; Vaziri ND; Moradi H
    J Card Fail; 2018 Apr; 24(4):266-275. PubMed ID: 29325796
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy.
    Shah AM; Claggett B; Prasad N; Li G; Volquez M; Jering K; Cikes M; Kovacs A; Mullens W; Nicolau JC; Køber L; van der Meer P; Jhund PS; Ibram G; Lefkowitz M; Zhou Y; Solomon SD; Pfeffer MA
    Circulation; 2022 Oct; 146(14):1067-1081. PubMed ID: 36082663
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF.
    Myhre PL; Prescott MF; Murphy SP; Fang JC; Mitchell GF; Ward JH; Claggett B; Desai AS; Solomon SD; Januzzi JL
    JACC Heart Fail; 2022 Feb; 10(2):119-128. PubMed ID: 35115085
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients.
    Oh JH; Lee JM; Lee HJ; Hwang J; Lee CH; Cho YK; Park HS; Yoon HJ; Chung JW; Kim H; Nam CW; Han S; Hur SH; Youn JC; Kim IC
    ESC Heart Fail; 2022 Aug; 9(4):2435-2444. PubMed ID: 35484930
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synergy between sacubitril and valsartan leads to hemodynamic, antifibrotic, and exercise tolerance benefits in rats with preexisting heart failure.
    Maslov MY; Foianini S; Mayer D; Orlov MV; Lovich MA
    Am J Physiol Heart Circ Physiol; 2019 Feb; 316(2):H289-H297. PubMed ID: 30461302
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON-HF trial.
    Lund LH; Savarese G; Venkateshvaran A; Benson L; Lundberg A; Donal E; Daubert JC; Oger E; Linde C; Hage C
    ESC Heart Fail; 2022 Feb; 9(1):164-177. PubMed ID: 34811954
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Effect of Sacubitril/Valsartan on Left Ventricular Myocardial Deformation in Heart Failure with Preserved Ejection Fraction (PARAMOUNT trial).
    Biering-Sørensen T; Lassen MCH; Shah A; Claggett B; Zile M; Pieske B; Pieske-Kraigher E; Voors A; Shi V; Lefkowitz M; Packer M; McMurray JJV; Solomon SD;
    J Card Fail; 2023 Jun; 29(6):968-973. PubMed ID: 37031887
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics and Pharmacodynamics of Sacubitril/Valsartan in Maintenance Hemodialysis Patients with Heart Failure.
    Feng Z; Wang X; Zhang L; Apaer R; Xu L; Ma J; Li X; Che H; Tang B; Xiong Y; Xia Y; Xiao J; Su X; Wang Y; Dou X; Chen J; Mei L; Xue Z; Kong Y; Li S; Zhang H; Lin T; Wen F; Fu X; Tao Y; Fu L; Li Z; Huang R; Ye Z; He C; Shi W; Liang X; Ke G; Liu S
    Blood Purif; 2022; 51(3):270-279. PubMed ID: 34753147
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sacubitril/valsartan ameliorates cardiac function and ventricular remodeling in CHF rats via the inhibition of the tryptophan/kynurenine metabolism and inflammation.
    Gan J; Wang Y; Deng Y; Zhang J; Wang S; Jiang X; Guo M; Song L
    Sci Rep; 2024 May; 14(1):12377. PubMed ID: 38811632
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sacubitril/valsartan combination enhanced cardiac glycophagy and prevented the progression of murine diabetic cardiomyopathy.
    Elshenawy DSA; Ramadan NM; Abdo VB; Ashour RH
    Biomed Pharmacother; 2022 Sep; 153():113382. PubMed ID: 36076522
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sacubitril/Valsartan Inhibits Cardiomyocyte Hypertrophy in Angiotensin II-Induced Hypertensive Mice Independent of a Blood Pressure-Lowering Effect.
    Tashiro K; Kuwano T; Ideishi A; Morita H; Idemoto Y; Goto M; Suematsu Y; Miura SI
    Cardiol Res; 2020 Dec; 11(6):376-385. PubMed ID: 33224383
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differential Effects of Sacubitril/Valsartan on Diastolic Function in Mice With Obesity-Related Metabolic Heart Disease.
    Croteau D; Qin F; Chambers JM; Kallick E; Luptak I; Panagia M; Pimentel DR; Siwik DA; Colucci WS
    JACC Basic Transl Sci; 2020 Sep; 5(9):916-927. PubMed ID: 33015414
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardioprotective effects of early intervention with sacubitril/valsartan on pressure overloaded rat hearts.
    Li X; Braza J; Mende U; Choudhary G; Zhang P
    Sci Rep; 2021 Aug; 11(1):16542. PubMed ID: 34400686
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of sacubitril/valsartan effects on left ventricular dynamics using 3D echocardiography and 3D strain in heart failure with reduced ejection fraction patients.
    Öz TK; Abdelnabi M; Fiore C; Almaghraby A; Cihan D; Babazade N; Haseeb Raza Naqvi S; Omar B; Dağdeviren B
    Minerva Cardiol Angiol; 2022 Aug; 70(4):431-438. PubMed ID: 34713680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.